There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inovio Pharmaceuticals (INO) and EDAP TMS (EDAP) with bullish sentiments.
Inovio Pharmaceuticals (INO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $13. The company’s shares closed yesterday at $2.49, close to its 52-week low of $2.15.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 0.7% and a 26.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Inovio Pharmaceuticals with a $10.50 average price target, representing a 321.7% upside. In a report issued on May 29, Cantor Fitzgerald also maintained a Buy rating on the stock with a $12 price target.
See today’s analyst top recommended stocks >>
EDAP TMS (EDAP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on EDAP TMS, with a price target of $6.50. The company’s shares closed yesterday at $2.80.
Ramakanth noted:
“We are maintaining our Buy rating of EDAP TMS and our 12-month price target of $6.50 per diluted ADS. We derived our price target based on the average of two valuation methods: 1) price-earnings multiple using 25x 2026 EPS estimate discounted at 12%; and 2) discounted cash flow analysis using a 2% terminal growth rate and discounting 2026 free cash flow estimate at a 12% discount rate. (1) commercial; (2) regulatory; (3) currency; (4) reimbursement; and (5) intellectual property.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -12.1% and a 29.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on EDAP TMS is a Moderate Buy with an average price target of $6.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
